1Noto D, eottone S, Baldassare Cefalu A, et al. Interleukin-6 plasma levels prediet with high sensitivity and specificity coronary stenosis detected by coronary angiography[ J]. Thromb Haemost, 2007,98 :1362 - 1367.
2Davis NE. Atherosclerosis-an inflammatory process [ J ] . J Insur Med, 2005,37 : 72 - 75.
3Cui R, Tieu B, Recinos A, et al.RhoA mediates angiotensin Ⅱ induced phospho-Ser536 nuclear factor kappaB/RelA subunit exchange on the interleukin - 6 promoter in VSMCs[ J]. Circ Res, 2006,99: 723 - 730.
4Park SY, Lee JH, Kim YK, et al.Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte ehemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation [ J ]. J Pharmacol Exp Ther, 2005, 312:1241 - 1248.
5Ross R. Atherosclerosis2an inflammatory disease[J]. N Engl J Med, 1999, 340 (2) : 115- 126.
6Wassmann S, Stumpfr M, Strehlow k, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin Ⅱ type Ⅰ receptor [J]. Circ Res, 2004, 94 (4) : 534 - 541.
9Libby P, Aikawa M. Mechanisms of plaque stabilization with statins [J]. Am J Cardiol, 2003, 91:4B - 8B.
二级参考文献52
1Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, et al.Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels.The Prospective Pravastatin Pooling project.Eur Heart J, 2002, 23 (3):207-215
2Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S).Lancet, 1994, 344:1 383-389
3Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary Atherosclerosis Prevention Study.J Am Med Assoc, 1998, 279 (20):1 615-622
4Plutzky J, Ridker PM.Statins for Stroke:The Second Story? Circulation, 2002, 103 (3):348-350
5Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al.Effect of pravastatin on outcomes after cardiac transplantation.N Engl J Med, 1995, 333 (10):621-627
6Wenke K, Meiser B, Thiery J, Nagel D, Scheidt WV, Steinbeck G, et al.Simvastatin reduces graft vessel disease and mortality after heart transplantation.Circulation, 1997, 96 (5):1 398-402
7Strandberg TE, Vanhanen H, Tikkanen MJ.Effect of statins on C-reactive protein with coronary artery disease.Lancet, 1999, 353(9147):118-119
8Rider PM, Rifai N, Pfeffer M, Sacks F, Braunwald E.For the cholesterol and recurrent event (CARE) investigators.Long-term effects of pravastatin on plasma concentration of C-reactive protein.Circulation, 1999, 100 (3):230-235
10Albert MA, Danielson E, Rifai N, Ridker PM.Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation / CRP Evaluation (PRINCE):A randomize trial and cohort study.J Am Med Assoc, 2001, 286 (1):64-70
5Libby P, Aikawa M. Mechanisms of plaque stabilization with stains. Am J Cardiol,2003,91:4B-8B.
6Noto D, Cottone S, Baldassare CA, et al. Interleukin-6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. Thromb Haemost,2007,98 : 1362-1367.
7Saenger AK, Jaffe AS. The use of biomarkers for the evaluation and treatment of patients with aetue coronary syndromes. Med Clin North Am, 2007,91:657-681.
8Cui R, Tieu B, Recinos A, etal. RhoA mediates angiotensin II-induced phospho-Ser536 nuclear factor kappaB/RelA subunit exchange on the in- terleukin-6 promoter in VSMCs. Cire Res,2006,99:723-730.
